The adaptive immune system restrains Alzheimer's disease pathogenesis by modulating microglial function

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 9, 2016, Pages E1316-E1325

  Marsh, Samuel E ^a,b   Abud, Edsel M ^a,b   Lakatos, Anita ^b   Karimzadeh, Alborz ^b   Yeung, Stephen T ^b,d   Davtyan, Hayk ^c   Fote, Gianna M ^a,b   Lau, Lydia ^b   Weinger, Jason G ^b,e   Lane, Thomas E ^b,f   Inlay, Matthew A ^b   Poon, Wayne W ^b   Blurton Jones, Mathew ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INSTITUTE FOR MOLECULAR MEDICINE   (United States)

^d UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^e Neurocentria   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's; Amyloid; IgG; Inflammation; Microglia

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; PHOSPHATIDYLINOSITOL 3 KINASE; PRESENILIN 1; PROTEIN KINASE SYK; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BLOOD BRAIN BARRIER; BONE MARROW TRANSPLANTATION; CELL ACTIVATION; CELL STRUCTURE; CHOROID PLEXUS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENTATE GYRUS; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; GENE EXPRESSION; HIPPOCAMPUS; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MICROGLIA; MOUSE; NATURAL KILLER CELL; NEUROPATHOLOGY; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; UPREGULATION; WESTERN BLOTTING; ADAPTATION; ANIMAL; BLOOD; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

ADAPTATION, PHYSIOLOGICAL; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; HUMANS; IMMUNOGLOBULIN G; MICE; MICROGLIA; PHAGOCYTOSIS;

EID: 84959432135     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1525466113     Document Type: Article

References (63)

1. Alzheimer's Association (2014) 2014 Alzheimer's disease facts and figures. Alzheimers Dement 10(2):e47-e92.
2. McAlpine FE, Tansey MG (2008) Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer's disease. J Inflamm Res 1:29-39.
3. Maier M, et al. (2008) Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci 28(25):6333-6341.
4. Wyss-Coray T, Rogers J (2012) Inflammation in Alzheimer disease - a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2(1):a006346.
5. Guillot-Sestier MV, Town T (2013) Innate immunity in Alzheimer's disease: A complex affair. CNS Neurol Disord Drug Targets 12(5):593-607.
6. Lee CY, Landreth GE (2010) The role of microglia in amyloid clearance from the AD brain. J Neural Transm (Vienna) 117(8):949-960.
7. Mosher KI, Wyss-Coray T (2014) Microglial dysfunction in brain aging and Alzheimer's disease. Biochem Pharmacol 88(4):594-604.
8. Heneka MT, et al. (2015) Neuroinflammation in Alzheimer's disease. Lancet Neurol 14(4):388-405.
9. Hickman SE, Allison EK, El Khoury J (2008) Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci 28(33):8354-8360.
10. Krabbe G, et al. (2013) Functional impairment of microglia coincides with beta-amyloid deposition in mice with Alzheimer-like pathology. PLoS One 8(4):e60921.
11. Bradshaw EM, et al.; Alzheimer Disease Neuroimaging Initiative (2013) CD33 Alzheimer's disease locus: Altered monocyte function and amyloid biology. Nat Neurosci 16(7):848-850.
12. Griciuc A, et al. (2013) Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 78(4):631-643.
13. Guerreiro R, et al.; Alzheimer Genetic Analysis Group (2013) TREM2 variants in Alzheimer's disease. N Engl J Med 368(2):117-127.
14. Jay TR, et al. (2015) TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. J Exp Med 212(3):287-295.
15. Wang Y, et al. (2015) TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 160(6):1061-1071.
16. Pellicanò M, et al. (2012) Immune profiling of Alzheimer patients. J Neuroimmunol 242(1-2):52-59.
17. Baruch K, et al. (2015) Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer's disease pathology. Nat Commun 6:7967.
18. Zenaro E, et al. (2015) Neutrophils promote Alzheimer's disease-like pathology and cognitive decline via LFA-1 integrin. Nat Med 21(8):880-886.
19. Oakley H, et al. (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: Potential factors in amyloid plaque formation. J Neurosci 26(40):10129-10140.
20. Dranoff G (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4(1):11-22.
21. Reiman EM, et al. (2012) Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: A case-control study. Lancet Neurol 11(12):1048-1056.
22. Potter R, et al. (2013) Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med 5(189):189ra77.
23. Mawuenyega KG, et al. (2010) Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330(6012):1774.
24. Wildsmith KR, Holley M, Savage JC, Skerrett R, Landreth GE (2013) Evidence for impaired amyloid β clearance in Alzheimer's disease. Alzheimers Res Ther 5(4):33.
25. Tarasoff-Conway JM, et al. (2015) Clearance systems in the brain - implications for Alzheimer disease. Nat Rev Neurol 11(8):457-470.
26. Zhang Y, et al. (2014) An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci 34(36):11929-11947.
27. Chakrabarty P, et al. (2015) IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron 85(3):519-533.
28. Guillot-Sestier MV, et al. (2015) Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. Neuron 85(3):534-548.
29. Guillot-Sestier MV, Doty KR, Town T (2015) Innate immunity fights Alzheimer's disease. Trends Neurosci 38(11):674-681.
30. Leinenga G, Götz J (2015) Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer's disease mouse model. Sci Transl Med 7(278):278ra33.
31. Deane R, et al. (2008) apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest 118(12):4002-4013.
32. Zlokovic BV (2013) Cerebrovascular effects of apolipoprotein E: Implications for Alzheimer disease. JAMA Neurol 70(4):440-444.
33. Elmore MR, et al. (2014) Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron 82(2):380-397.
34. Davtyan H, et al. (2010) DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice. Gene Ther 17(2):261-271.
35. Davtyan H, Petrushina I, Ghochikyan A (2014) Immunotherapy for Alzheimer's disease: DNA- and protein-based epitope vaccines. Methods Mol Biol 1143:259-281.
36. Koenigsknecht-Talboo J, Landreth GE (2005) Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci 25(36):8240-8249.
37. García-García E, Rosales C (2002) Signal transduction during Fc receptor-mediated phagocytosis. J Leukoc Biol 72(6):1092-1108.
38. Sudduth TL, Greenstein A, Wilcock DM (2013) Intracranial injection of Gammagard, a human IVIg, modulates the inflammatory response of the brain and lowers Aβ in APP/PS1 mice along a different time course than anti-Aβ antibodies. J Neurosci 33(23):9684-9692.
39. Knight EM, Gandy S (2014) Immunomodulation and AD - down but not out. J Clin Immunol 34(Suppl 1):S70-S73.
40. Relkin N (2014) Clinical trials of intravenous immunoglobulin for Alzheimer's disease. J Clin Immunol 34(Suppl 1):S74-S79.
41. Counts SE, et al. (2014) Intravenous immunoglobulin (IVIG) treatment exerts antioxidant and neuropreservatory effects in preclinical models of Alzheimer's disease. J Clin Immunol 34(Suppl 1):S80-S85.
42. Jordão JF, et al. (2013) Amyloid-β plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound. Exp Neurol 248:16-29.
43. Burgess A, et al. (2014) Alzheimer disease in a mouse model: MR imaging-guided focused ultrasound targeted to the hippocampus opens the blood-brain barrier and improves pathologic abnormalities and behavior. Radiology 273(3):736-745.
44. Carrillo MC, et al. (2013) Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease. Alzheimers Dement 9(2):123-131.e1.
45. 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology 85(8):692-700.
46. Ances BM, Ellis RJ (2007) Dementia and neurocognitive disorders due to HIV-1 infection. Semin Neurol 27(1):86-92.
47. Brew BJ, Pemberton L, Blennow K, Wallin A, Hagberg L (2005) CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology 65(9):1490-1492.
48. Soontornniyomkij V, et al. (2012) Cerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriers. AIDS 26(18):2327-2335.
49. Xu W, Banchereau J (2014) The antigen presenting cells instruct plasma cell differentiation. Front Immunol 4:504.
50. Sakaguchi S, Yamaguchi T, Nomura T, Ono M (2008) Regulatory T cells and immune tolerance. Cell 133(5):775-787.
51. Poduslo JF, Curran GL, Berg CT (1994) Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc Natl Acad Sci USA 91(12):5705-5709.
52. Fuller JP, Stavenhagen JB, Teeling JL (2014) New roles for Fc receptors in neurodegeneration-the impact on immunotherapy for Alzheimer's disease. Front Neurosci 8:235.
53. Ransohoff RM, Engelhardt B (2012) The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol 12(9):623-635.
54. Schwartz M, Baruch K (2014) The resolution of neuroinflammation in neurodegeneration: Leukocyte recruitment via the choroid plexus. EMBO J 33(1):7-22.
55. Baruch K, et al. (2014) Aging. Aging-induced type I interferon response at the choroid plexus negatively affects brain function. Science 346(6205):89-93.
56. Bergen AA, Kaing S, Ten Brink JB, Gorgels TG, Janssen SF; Netherlands Brain Bank (2015) Gene expression and functional annotation of human choroid plexus epithelium failure in Alzheimer's disease. BMC Genomics 16(1):956.
57. Schlachetzki F, Zhu C, Pardridge WM (2002) Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. J Neurochem 81(1):203-206.
58. Deane R, et al. (2005) IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci 25(50):11495-11503.
59. Cao X, et al. (1995) Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity 2(3):223-238.
60. Blurton-Jones M, et al. (2009) Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci USA 106(32):13594-13599.
61. Schmued L, et al. (2012) Introducing Amylo-Glo, a novel fluorescent amyloid specific histochemical tracer especially suited for multiple labeling and large scale quantification studies. J Neurosci Methods 209(1):120-126.
62. Webster SD, et al. (2001) Antibody-mediated phagocytosis of the amyloid beta-peptide in microglia is differentially modulated by C1q. J Immunol 166(12):7496-7503.
63. Blasi E, Barluzzi R, Bocchini V, Mazzolla R, Bistoni F (1990) Immortalization of murine microglial cells by a v-raf/v-myc carrying retrovirus. J Neuroimmunol 27(2-3):229-237.